Therefore, we assessed the methylation frequency of CLDN11 in 125 CRC samples, and analyzed the associations between aberrantly methylated CLDN11 and the progression of CRC, along with other clinical characteristics, such as gender, age, tumor size and differentiation. This evidence concerns the gene CLDN11 and neoplasm.